human gbm cell lines  (ATCC)

Journal: Journal of Biomedical Science

Article Title: IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment

doi: 10.1186/s12929-025-01126-w

Figure Lengend Snippet: IL-19 expression in tumor associated with poor prognosis in patients with GBM. A Survival probability of patients with GBM in two groups with high ( n = 34) and low IL-19 ( n = 45) expression obtained from RNA-seq data in TCGA database. B Survival probability of patients with GBM in two groups with large ( n = 32) and small ( n = 47) log 2 fold change in relative IL-19 expression to TATA-binding protein expression level observed from RNA microarray data in TCGA database and in C large fold change group ( n = 11) and low fold change group ( n = 11) in Taiwan GBM study cohort. The p values for the log-rank test are indicated in the survival probability graph. D IL-19 expression levels in human GBM cell lines (GBM8401, GBM8901, and U87 cells) and murine GBM cell line (GL261) were determined through flow cytometry. Light-gray histogram represents isotype control antibody staining. E Flow cytometric gating for tumor-infiltrating microglia (CD45 dim CD11b dim ) and MO-MDSCs (CD45 hi CD11b hi Ly6C + Ly6G − ) in GL261 tumor–bearing mice. Blue histogram represents isotype control antibody staining to examine IL-19 expression level in brain-infiltrating lymphocytes. F Immunofluorescent staining of the IL-19 (red), M2 TAM Marker CD206 (green) and the pan-macrophage/microglia marker Iba1 (green) in intratumoral and peritumoral region of human GBM tissue. White arrows indicate CD206 + IL-19 + or Iba1 + IL-19 + cells. Scale bar: 50 μM

Article Snippet: Human GBM cell line, including U87, GBM8401, GBM8901, and DBTRG-05MG cell lines were purchased from the Bioresource Collection and Research Center (Taiwan).

Techniques: Expressing, RNA Sequencing Assay, Binding Assay, Microarray, Flow Cytometry, Control, Staining, Marker

Journal: Journal of Biomedical Science

Article Title: IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment

doi: 10.1186/s12929-025-01126-w

Figure Lengend Snippet: Effects of IL-19 on TMZ-resistant GBM migration and invasion. A Expression levels of IL-19, IL-20RA, and IL-20RB in DBTRG and DBTRG/TMZ-R cells were analyzed by Western blot. B Human GBM cell (U118) and TMZ-resistant cells (GL261/TMZ-R, DBTRG/TMZ-R) were treated with IL-19 (100 ng/mL) for various duration and WISP1 expression was analyzed through Western blotting. C Effect of blocking WISP1 on IL-19-induced GBM cell migration and invasion. U118 and DBTRG/TMZ-R cells were treated with IL-19 (100 ng/mL) in the presence of isotype ctrl. or WISP1 antibodies (1 μg/mL) for 24 h, and invasion was analyzed through a Matrigel-coated transwell migration assay; n = 8, one-way ANOVA; **** p < 0.0001. Scale bar: 50 μM. D The effect of AKT inhibitor IV (1 μM) on IL-19/WISP1 signaling pathway of U118 cells in the presence of absence of IL-19 (100 ng/mL) for 2 h. Expression level of pAKT, p-β-catenin, WISP1, and GAPDH were determined by Western blot. E Effects of Il-19 KO on migration and invasion of GL261/TMZ-R cells. Migration and invasion ability of Ctrl and two Il-19 KO clones (KO#1 and KO#2) were determined through Matrigel-coated transwell migration assay; n = 3, one-way ANOVA; ** p < 0.01, *** p < 0.001. F IL-19, pAKT, WISP1, and GAPDH expression levels in Ctrl and IL-19 KO GL261/TMZ-R cells were determined by Western blot

Article Snippet: Human GBM cell line, including U87, GBM8401, GBM8901, and DBTRG-05MG cell lines were purchased from the Bioresource Collection and Research Center (Taiwan).

Techniques: Migration, Expressing, Western Blot, Blocking Assay, Transwell Migration Assay, Clone Assay

Journal: Journal of Biomedical Science

Article Title: IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment

doi: 10.1186/s12929-025-01126-w

Figure Lengend Snippet: CHOL-PEG-SPIO-IL19 Synthesis process and characterization in vitro. A Synthetic scheme of IL-19 antibodies and CHOL-PEG polymer conjugated with amino-coated SPIO nanoparticles. 1. Amino-coated SPIO nanoparticles were modified with maleimide through reaction with sulfo-SMCC. 2. IL-19 antibodies were thiolated with iminothiolane, and TCEP was added to reduce disulfide bonds. 3. The maleimide-functionalized SPIO nanoparticles were mixed with the thiolated antibody solution and CHOL-PEG polymer to form CHOL-PEG and antibody-conjugated SPIO nanoparticles. B The size distributions of CHOL-PEG-SPIO-IL19 and unconjugated SPIO nanoparticles were determined through DLS measurement, as shown on the volume distribution graph. C TEM images of unconjugated SPIO and CHOL-PEG-SPIO-IL19 (scale bar = 20 nm). Statistical analysis indicated a significant difference among the particle size of CHOL-PEG-SPIO-IL19 and SPIO nanoparticles (n = 10 per group). D FT-IR spectrum of CHOL-PEG, IL-19 antibody, CHOL-PEG-SPIO-IL19 and unconjugated SPIO nanoparticles. The IR spectrum of Cholesterol-PEG polymer is characterized by peak at approximately 2854 cm −1 due to C-H stretching. E Evaluation of CHOL-PEG-SPIO-IL19 nanoparticles targeting specificity through IF staining. DBTRG cells were incubated with IL-19 antibodies, isotype control antibodies (mouse IgG2b antibody), SPIO nanoparticles, and CHOL-PEG-SPIO-IL19 nanoparticles, and then stained with FITC goat anti-mouse IgG2b antibodies. Green, IL-19; blue, DAPI. F Flow cytometry analysis for intracellular IL-19 expression in human GBM cells by using CHOL-PEG-SPIO-IL19 nanoparticles. DBTRG cells were stained with SPIO nanoparticles, CHOL-PEG-SPIO-IL19 nanoparticles, IL-19 antibodies, or isotype control antibodies (mouse IgG2b antibody) and then stained with FITC goat anti-mouse IgG2b antibodies. G Detection of CHOL-PEG-SPIO-IL19 in T2-weighted MRI images. Echo time curve fitting of CHOL-PEG-SPIO-IL19 phantoms in various known concentrations was measured using 7 T MRI. T2 relaxation time of CHOL-PEG-SPIO-IL19 in known Fe concentrations (n = 3 for each concentration). Corresponding signal intensity images of CHOL-PEG-SPIO-IL19 standards (0–15.7 μg/mL) measured using T2-weighted images

Article Snippet: Human GBM cell line, including U87, GBM8401, GBM8901, and DBTRG-05MG cell lines were purchased from the Bioresource Collection and Research Center (Taiwan).

Techniques: In Vitro, Polymer, Modification, Staining, Incubation, Control, Flow Cytometry, Expressing, Concentration Assay

Journal: Scientific Reports

Article Title: Pan-cancer analysis identifies ADAM12 as a prognostic biomarker and indicator of immune infiltration in glioma

doi: 10.1038/s41598-025-90121-0

Figure Lengend Snippet: The expression levels of ADAM12 in various tumors. ( A ) ADAM12 gene expression in Breast invasive carcinoma (BRCA), Glioblastoma-Lower Grade Glioma(GBMLGG), Bladder Cancer (BLCA), Esophageal Carcinoma (ESCA), Kidney Chromophobe (KICH),Kidney Clear Cell Carcinoma (KIRC), Kidney Papillary Cell Carcinoma (KIRP), Ovarian Cancer (OV), Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Adrenocortical Cancer (ACC) using GEPIA2. ( B – L ) The correlation between ADAM12 expression and different cancer stages/histological grades of tumors. ( B ) GBMLGG, ( C ) GBM, ( D ) BRCA, ( E ) KIRC, ( F ) KIRP, ( G ) KICH, ( H ) BLCA, ( I ) LIAD, ( J ) LIHC, ( K ) ACC, ( L ) OV.

Article Snippet: Human glioblastoma multiforme (GBM) cell lines (U87MG and U251MG) were sourced from Procell Life Science & Technology Co., Ltd (Wuhan, China) and verified via short tandem repeat (STR) profiling.

Techniques: Expressing